Enstilar泡沫剂治疗银屑病的效果如何？

Author: Medicalhalo

Release time: 2025-10-19 11:44:20

The effect of treating psoriasis is obvious, and patients in need can use medication under the guidance of a doctor.

Drug introduction

Psoriasis is a very common chronic inflammatory skin disease that affects 3% of people, and 75% of people with psoriasis have mild disease. For this reason, topical treatment is the most common treatment for psoriasis, also because it can be easily combined with systemic treatment. In this case, calcipotriol/betamethasone dipropionate foam (Enstilar®) is a fixed-dose combination foam formulation of a synthetic vitamin D3 analogue and a synthetic corticosteroid indicated for the topical treatment of plaque psoriasis in adults.

Calcipotriol/betamethasone (Cal/BD) fixed-dose combination has become a first-line treatment option due to its efficacy and once-daily application. Different Cal/BD formulations, such as ointments, gels (topical suspensions), and aerosol foams, have been approved by the U.S. Food and Drug Administration.

Enstilar (Cal/BD preparation) is an effective drug for the treatment of psoriasis. Cal/BD foam spray is more effective than ointment or gel preparations. In the treatment of psoriasis, it has a disruptive effect not only on mild psoriasis, but also on moderate psoriasis, as well as severe psoriasis combined with certain systemic treatments.

A study evaluated the efficacy and tolerability of a novel calcipotriol 50 µg/g combined with betamethasone 0.5 mg/g (Cal/BD foam, Enstilar®) in the treatment of psoriasis vulgaris under daily living conditions.

Results: At baseline, patients' psoriasis severity based on Investigator Global Assessment (IGA) was mild (41.81%), moderate (49.63%), and severe (8.31%). After 4 weeks of treatment, 49% of patients achieved IGA clearance/almost clearance. The average affected body surface area decreased from 12.91 to 7.55%, and the PASI decreased from 10.4 to 5.2 (p <0.0001). Treatment was successful in 43% of patients with severe IGA (IGA = 0/1 and ≥2 steps improvement). 93% of patients did not experience any adverse events.

Conclusion: The novel Cal/BD foam showed convincing efficacy and tolerability in daily clinical practice, especially in patients with more severe disease manifestations.